COO · Cooper Companies, Inc. · Financials

$56.53 -0.10 (-0.18%) At close · Sep 30

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$10.86B

190.16M

Volume · Sep 30 4.9M Avg daily vol (3M) 3.05M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$4.09B +5.1%

FY2025

Net Income

$374.9M -4.4%

FY2025

Gross Margin

65.54% -1.1pp

FY2025

Operating Margin

16.69% -1.4pp

FY2025

Diluted EPS

$1.87 -4.6%

FY2025

Operating Cash Flow

$796.1M +12.2%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+7.3%	+11.0%	+8.6%	$4.23B – $4.25B	$4.24B	$4.09B	$3.9B^G	$3.59B	$3.31B^G	$2.92B^G	$2.43B	$2.65B	$2.53B	$2.14B	$1.97B	$1.8B	$1.72B	$1.59B	$1.45B	$1.33B	$1.16B	$1.08B	$1.05B
Cost of Revenue	+6.5%	+9.5%	+6.9%	—	$1.44B	$1.41B	$1.3B	$1.24B	$1.17B	$966.7M	$896.1M	$896.6M	$900.5M	$773.2M	$793.7M	$726.8M	$626.21M	$560.92M	$521.13M	$526.03M	$481.79M	$483.93M	$437.35M
Gross Profit	+7.8%	+11.8%	+9.6%	—	$2.79B	$2.68B	$2.6B	$2.36B	$2.14B	$1.96B	$1.53B	$1.76B	$1.63B	$1.37B	$1.17B	$1.07B	$1.09B	$1.03B	$924.01M	$804.8M	$676.72M	$596.49M	$610.03M
Gross Margin	—	—	—	—	—	65.54%	66.64%	65.62%	64.67%	66.92%	63.14%	66.21%	64.45%	63.85%	59.65%	59.56%	63.55%	64.67%	63.94%	60.47%	58.41%	55.21%	58.24%
Research & Development	+16.0%	+13.0%	+9.5%	—	$169.8M	$172.2M	$155.1M	$137.4M	$110.3M	$92.7M	$93.3M	$86.7M	$84.8M	$69.2M	$65.4M	$69.6M	$66.26M	$58.83M	$51.73M	$43.58M	$35.27M	$33.3M	$35.47M
Selling, General & Administrative	+6.6%	+10.4%	+8.6%	—	$1.89B	$1.63B	$1.53B	$1.5B	$1.34B	$1.21B	$992.5M	$996.2M	$973.3M	$799.1M	$722.8M	$712.5M	$683.12M	$610.74M	$564.9M	$513.14M	$433.06M	$391.59M	$429.3M
Amortization of Intangibles	+3.5%	+7.7%	+14.5%	—	$192.4M	$199.2M	$201.2M	$186.2M	$179.5M	$146.1M	$137.2M	$145.8M	$146.7M	$68.4M	$60.8M	$51.5M	$35.71M	$30.24M	$23.98M	$20.53M	$18.06M	$17.86M	$16.77M
Depreciation & Amortization	+2.9%	—	+7.0%	—	$384M	$377.4M	$375.1M	$367.7M	$346.1M	$309.3M	—	$280.8M	$275.1M	$188.4M	$198.3M	$191.4M	$138.2M	$125.35M	$111.21M	$98.15M	$94M	$92.6M	$82.19M
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0	$0	$424K	$3.89M	$1.52M
Operating Income	+10.4%	+17.0%	+11.2%	—	$544.2M	$682.9M	$705.7M	$533.1M	$507.6M	$505.8M	$311.8M	$546.7M	$403.1M	$429.1M	$324.1M	$236.7M	$306.49M	$305.95M	$283.4M	$227.56M	$189.91M	$149.86M	$126.96M
Operating Margin	—	—	—	—	—	16.69%	18.12%	14.84%	15.34%	17.31%	12.83%	20.6%	15.92%	20.06%	16.48%	13.17%	17.84%	19.27%	19.61%	17.1%	16.39%	13.87%	12.12%
EBITDA	+7.5%	—	+9.5%	—	$928.2M	$1.06B	$1.08B	$900.8M	$853.7M	$815.1M	—	$827.5M	$678.2M	$617.5M	$522.4M	$428.1M	$444.69M	$431.29M	$394.61M	$325.71M	$283.91M	$242.46M	$209.15M
Interest Expense	+20.4%	+22.1%	+18.6%	—	$89.2M	$100M	$114.3M	$105.3M	$57.3M	$23.1M	$36.8M	$68M	$82.7M	$33.4M	$26.2M	$18.1M	$7.97M	$9.17M	$11.77M	$17.34M	$36.67M	$44.14M	$53.03M
Other Non-Operating Income	—	—	—	—	$7.4M	-$16.4M	-$9.1M	-$14.9M	$25M	$8.8M	-$8.5M	-$1.3M	$11.5M	-$1.7M	-$2.3M	-$3.1M	-$1.99M	$1.41M	$229K	-$963K	-$1.07M	$7.29M	$28K
Pretax Income	+6.0%	+16.3%	+10.1%	—	$462.4M	$566.5M	$582.3M	$412.9M	$475.3M	$491.5M	$266.5M	$477.4M	$331.9M	$394M	$295.6M	$215.5M	$296.53M	$312.27M	$275.45M	$192.76M	$124.43M	$114.83M	$73.96M
Income Tax	+28.9%	+46.8%	+33.8%	—	-$107.9M	$191.6M	$190M	$118.7M	$89.5M	-$2.45B	$28.1M	$10.7M	$192M	$21.1M	$20.7M	$10.4M	$24.71M	$15.37M	$26.81M	$17.33M	$11.62M	$14.28M	$10.01M
Net Income	-1.0%	+9.5%	+6.3%	—	$570.3M	$374.9M	$392.3M	$294.2M	$385.8M	$2.94B	$238.4M	$466.7M	$139.9M	$372.9M	$273.9M	$203.5M	$269.86M	$296.15M	$248.34M	$175.43M	$112.8M	$100.55M	$63.96M
Net Margin	—	—	—	—	—	9.16%	10.07%	8.19%	11.66%	100.76%	9.81%	17.59%	5.52%	17.43%	13.93%	11.32%	15.71%	18.65%	17.18%	13.18%	9.74%	9.31%	6.11%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	—	—	—	—	—	—	$0	$0	$1M	$1.6M	$1.97M	$755K	$305K	$0	$0	—	—
Net Income Available to Common Stockholders	-6.1%	—	—	—	—	—	—	—	$385.8M	$2.94B	$238.4M	$466.7M	—	—	—	—	—	—	—	—	—	—	—
Comprehensive Income	+225.3%	—	+33.2%	—	—	—	—	—	—	$3.08B	$213.5M	$450.3M	$89.3M	$487.2M	-$24M	$119.2M	$180.68M	$313.12M	$235.21M	$174.65M	$108.39M	$112.87M	—
EPS (Basic) USD/shares	-1.2%	+9.2%	+6.0%	—	$2.94	$1.88	$1.97	$1.49	$1.95	$14.95	$1.21	$2.36	$0.71	$1.91	$1.41	$1.05	$1.40	$1.52	$1.30	$0.94	$0.62	$0.56	$0.36
EPS (Diluted) USD/shares	-1.2%	+9.2%	+6.1%	$4.51 – $4.55*	$2.92	$1.87	$1.96^G	$1.48	$1.94^G	$14.79^G	$1.20	$2.33	$0.70	$1.88	$1.40	$1.04	$1.38	$1.49	$1.26	$0.91	$0.61	$0.55	$0.36
Shares Outstanding (Basic Avg) shares	+0.3%	+0.3%	+0.3%	—	—	199.1M	198.9M	197.9M	197.4M	196.8M	196.4M	197.6M	196.4M	195.6M	194M	194M	192.24M	194.46M	191.65M	187.62M	182.12M	180.69M	179.98M
Shares Outstanding (Diluted Avg) shares	+0.2%	+0.2%	+0.2%	—	—	200M	200.4M	199.3M	198.8M	199.2M	198.4M	200M	198.8M	198.4M	196M	196.8M	195.84M	198.74M	196.61M	193.24M	186.02M	181.91M	180.47M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $1.03B in buybacks, $46.22M in dividends.

Debt Profile

Completed filing coverage through Dec 23, 2025 · latest terminal result Sep 9, 2026

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

3.13×

Peer median 2.40×

EV/EBIT

24.34×

Peer median 32.06×

P/E (TTM)

19.56×

Peer median 34.91×

Peer medians compare against the 24 similar-size Medical Instruments & Supplies companies (of 47 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Coopervision Segment	$2,743,800,000	$2,609,400,000	$2,423,700,000	$2,243,300,000	$2,152,000,000	$1,843,000,000	$1,972,900,000	$1,882,000,000
Coopersurgical Segment	$1,348,600,000	$1,286,000,000	$1,169,500,000	$1,065,100,000	$770,500,000	$587,900,000	$680,500,000	$650,800,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$2,054,000,000	$1,965,900,000	$1,812,200,000	$1,638,500,000	$1,339,200,000	$1,103,600,000	$1,211,800,000	$1,162,200,000
Europe	$1,253,200,000	$1,155,900,000	$1,041,200,000	$987,200,000	$957,900,000	$789,800,000	$854,800,000	$846,500,000
Rest of the World	$785,200,000	$773,600,000	$739,800,000	$682,700,000	$625,400,000	$537,500,000	$586,800,000	$524,100,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Sphere Other	$1,392,500,000	$1,352,200,000	$1,289,300,000	$1,241,500,000	—	—	—	—
Toric and Multifocal	$1,351,300,000	$1,257,200,000	$1,134,400,000	$1,001,800,000	—	—	—	—
Office and Surgical	$824,000,000	$774,700,000	$689,500,000	$633,600,000	—	—	—	—
Fertility	$524,600,000	$511,300,000	$960,000,000	$863,000,000	$638,400,000	$229,100,000	$258,100,000	$250,400,000
Multifocal Lens	—	—	$305,700,000	$528,800,000	—	$197,000,000	$202,900,000	$196,600,000
Non Single Use Sphere and Other	—	—	$583,900,000	$1,159,800,000	—	$518,800,000	$581,800,000	$573,900,000
Office and Surgical Products	—	—	$689,500,000	$1,267,200,000	$902,600,000	$358,800,000	$422,400,000	$400,400,000
Single Use Sphere Lens	—	—	$705,400,000	$1,323,200,000	—	$529,000,000	$568,200,000	$520,100,000
Toric Lens	—	—	$828,700,000	$1,474,800,000	$1,395,000,000	$598,200,000	$620,000,000	$591,400,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Cooper Vision Segment	$729,600,000	$676,200,000	$587,700,000	$494,300,000	$481,300,000	$375,700,000	$506,400,000	$479,800,000
Cooper Surgical Segment	$43,400,000	$118,300,000	$16,100,000	$67,100,000	$71,800,000	-$14,700,000	$87,900,000	-$19,900,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Coopervision Segment	26.6%	25.9%	24.2%	22%	22.4%	20.4%	25.7%	25.5%
Coopersurgical Segment	3.2%	9.2%	1.4%	6.3%	9.3%	-2.5%	12.9%	-3.1%

Key facts CIK 711404 CUSIP 216648501 13F (30d) 18 filings 14 filers Visit website Investor relations